HOOKIPA Pharma (HOOK)
(Real Time Quote from BATS)
$5.20 USD
-0.01 (-0.19%)
Updated Aug 30, 2024 12:32 PM ET
2-Buy of 5 2
C Value F Growth D Momentum D VGM
HOOKIPA Pharma Inc. (HOOK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$37.80 | $60.00 | $15.00 | 625.53% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for HOOKIPA Pharma Inc. comes to $37.80. The forecasts range from a low of $15.00 to a high of $60.00. The average price target represents an increase of 625.53% from the last closing price of $5.21.
Analyst Price Targets (5 )
Broker Rating
HOOKIPA Pharma Inc. currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 80% and 20% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 20%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/HOOK.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.20 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/26/2024 | JMP Securities | Roy Buchanan | Not Available | Strong Buy |
7/24/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
6/5/2024 | H.C. Wainwright & Co. | Arthur He | Strong Buy | Strong Buy |
4/1/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
3/25/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 5 |
Average Target Price | $37.80 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -1.59 |